WO2023033551A1 - mRNA 캡 유사체와 및 이의 용도 - Google Patents
mRNA 캡 유사체와 및 이의 용도 Download PDFInfo
- Publication number
- WO2023033551A1 WO2023033551A1 PCT/KR2022/013062 KR2022013062W WO2023033551A1 WO 2023033551 A1 WO2023033551 A1 WO 2023033551A1 KR 2022013062 W KR2022013062 W KR 2022013062W WO 2023033551 A1 WO2023033551 A1 WO 2023033551A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- formula
- compound
- mrna
- salt
- monopivaloyl
- Prior art date
Links
- 108020004999 messenger RNA Proteins 0.000 title claims abstract description 116
- 150000001875 compounds Chemical class 0.000 claims abstract description 177
- 238000000034 method Methods 0.000 claims abstract description 61
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 39
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 38
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 19
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 13
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 80
- 150000003839 salts Chemical class 0.000 claims description 40
- 239000000203 mixture Substances 0.000 claims description 37
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims description 24
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 22
- 150000001768 cations Chemical class 0.000 claims description 14
- 229910052739 hydrogen Inorganic materials 0.000 claims description 11
- 238000011065 in-situ storage Methods 0.000 claims description 11
- 229910052757 nitrogen Inorganic materials 0.000 claims description 11
- 229910052799 carbon Inorganic materials 0.000 claims description 10
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 claims description 10
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 claims description 8
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 claims description 8
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 claims description 8
- 229910052708 sodium Inorganic materials 0.000 claims description 7
- 230000007935 neutral effect Effects 0.000 claims description 6
- 239000011701 zinc Substances 0.000 claims description 6
- 229930024421 Adenine Natural products 0.000 claims description 5
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 claims description 5
- 229960000643 adenine Drugs 0.000 claims description 5
- 229940104302 cytosine Drugs 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- UBLQIESZTDNNAO-UHFFFAOYSA-N n,n-diethylethanamine;phosphoric acid Chemical compound [O-]P([O-])([O-])=O.CC[NH+](CC)CC.CC[NH+](CC)CC.CC[NH+](CC)CC UBLQIESZTDNNAO-UHFFFAOYSA-N 0.000 claims description 4
- 229940035893 uracil Drugs 0.000 claims description 4
- 239000011592 zinc chloride Substances 0.000 claims description 4
- 235000005074 zinc chloride Nutrition 0.000 claims description 4
- 239000008346 aqueous phase Substances 0.000 claims description 3
- 229910052749 magnesium Inorganic materials 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 abstract description 31
- 239000000126 substance Substances 0.000 abstract description 6
- 238000006243 chemical reaction Methods 0.000 description 60
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 44
- 239000000243 solution Substances 0.000 description 42
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 38
- 238000004519 manufacturing process Methods 0.000 description 34
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 description 33
- -1 guanosine nucleoside Chemical class 0.000 description 32
- 238000000746 purification Methods 0.000 description 30
- 238000003786 synthesis reaction Methods 0.000 description 25
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 24
- 239000002585 base Substances 0.000 description 24
- 238000013518 transcription Methods 0.000 description 24
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 23
- 230000015572 biosynthetic process Effects 0.000 description 23
- 229940029575 guanosine Drugs 0.000 description 23
- 230000035897 transcription Effects 0.000 description 23
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 21
- 101150113223 pppA gene Proteins 0.000 description 21
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 20
- MIKUYHXYGGJMLM-GIMIYPNGSA-N Crotonoside Natural products C1=NC2=C(N)NC(=O)N=C2N1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O MIKUYHXYGGJMLM-GIMIYPNGSA-N 0.000 description 19
- NYHBQMYGNKIUIF-UHFFFAOYSA-N D-guanosine Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(CO)C(O)C1O NYHBQMYGNKIUIF-UHFFFAOYSA-N 0.000 description 19
- 238000005481 NMR spectroscopy Methods 0.000 description 19
- 210000004027 cell Anatomy 0.000 description 19
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 19
- 238000000338 in vitro Methods 0.000 description 19
- 230000002829 reductive effect Effects 0.000 description 19
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 18
- 239000012153 distilled water Substances 0.000 description 18
- 230000008569 process Effects 0.000 description 18
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 15
- YQTCQNIPQMJNTI-UHFFFAOYSA-N 2,2-dimethylpropan-1-one Chemical group CC(C)(C)[C]=O YQTCQNIPQMJNTI-UHFFFAOYSA-N 0.000 description 14
- 239000002773 nucleotide Substances 0.000 description 13
- 125000003729 nucleotide group Chemical group 0.000 description 13
- 238000003756 stirring Methods 0.000 description 13
- 239000007858 starting material Substances 0.000 description 12
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 12
- JQZJEEMWFCMAQK-IDTAVKCVSA-N 2-amino-9-[(2R,3R,4S,5R)-5-[[tert-butyl(dimethyl)silyl]oxymethyl]-3,4-dihydroxyoxolan-2-yl]-1H-purin-6-one Chemical compound CC(C)(C)[Si](C)(C)OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c1nc(N)[nH]c2=O JQZJEEMWFCMAQK-IDTAVKCVSA-N 0.000 description 11
- OGHAROSJZRTIOK-KQYNXXCUSA-O 7-methylguanosine Chemical compound C1=2N=C(N)NC(=O)C=2[N+](C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OGHAROSJZRTIOK-KQYNXXCUSA-O 0.000 description 11
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 10
- 239000000543 intermediate Substances 0.000 description 10
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
- XKMLYUALXHKNFT-UUOKFMHZSA-N Guanosine-5'-triphosphate Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XKMLYUALXHKNFT-UUOKFMHZSA-N 0.000 description 9
- 108060001084 Luciferase Proteins 0.000 description 9
- 239000005089 Luciferase Substances 0.000 description 9
- 239000007864 aqueous solution Substances 0.000 description 9
- 239000012044 organic layer Substances 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 8
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 8
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 8
- HAXFWIACAGNFHA-UHFFFAOYSA-N aldrithiol Chemical compound C=1C=CC=NC=1SSC1=CC=CC=N1 HAXFWIACAGNFHA-UHFFFAOYSA-N 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 8
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 7
- 102000004190 Enzymes Human genes 0.000 description 7
- 108090000790 Enzymes Proteins 0.000 description 7
- 239000000872 buffer Substances 0.000 description 7
- 239000013078 crystal Substances 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 238000001727 in vivo Methods 0.000 description 7
- 239000002994 raw material Substances 0.000 description 7
- 235000017557 sodium bicarbonate Nutrition 0.000 description 7
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 7
- 238000011282 treatment Methods 0.000 description 7
- 241000180579 Arca Species 0.000 description 6
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 238000009396 hybridization Methods 0.000 description 6
- JBFYUZGYRGXSFL-UHFFFAOYSA-N imidazolide Chemical compound C1=C[N-]C=N1 JBFYUZGYRGXSFL-UHFFFAOYSA-N 0.000 description 6
- 230000001965 increasing effect Effects 0.000 description 6
- 239000002777 nucleoside Substances 0.000 description 6
- 239000012071 phase Substances 0.000 description 6
- 229920006395 saturated elastomer Polymers 0.000 description 6
- 239000011734 sodium Substances 0.000 description 6
- 230000014616 translation Effects 0.000 description 6
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 5
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 5
- VAYGXNSJCAHWJZ-UHFFFAOYSA-N dimethyl sulfate Chemical compound COS(=O)(=O)OC VAYGXNSJCAHWJZ-UHFFFAOYSA-N 0.000 description 5
- RQFCJASXJCIDSX-UUOKFMHZSA-N guanosine 5'-monophosphate Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O RQFCJASXJCIDSX-UUOKFMHZSA-N 0.000 description 5
- 235000013928 guanylic acid Nutrition 0.000 description 5
- 238000005342 ion exchange Methods 0.000 description 5
- 239000011777 magnesium Substances 0.000 description 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 5
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 5
- 239000011541 reaction mixture Substances 0.000 description 5
- 229910052938 sodium sulfate Inorganic materials 0.000 description 5
- 235000011152 sodium sulphate Nutrition 0.000 description 5
- 238000013519 translation Methods 0.000 description 5
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Substances OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 4
- KJUGUADJHNHALS-UHFFFAOYSA-N 1H-tetrazole Chemical compound C=1N=NNN=1 KJUGUADJHNHALS-UHFFFAOYSA-N 0.000 description 4
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 4
- SBASPRRECYVBRF-KQYNXXCUSA-N 7-methylguanosine 5'-diphosphate Chemical compound C1=2N=C(N)NC(=O)C=2[N+](C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)([O-])=O)[C@@H](O)[C@H]1O SBASPRRECYVBRF-KQYNXXCUSA-N 0.000 description 4
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 4
- 101150077194 CAP1 gene Proteins 0.000 description 4
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 4
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 4
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 4
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 4
- 229960005305 adenosine Drugs 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 230000000295 complement effect Effects 0.000 description 4
- 238000003818 flash chromatography Methods 0.000 description 4
- 239000010410 layer Substances 0.000 description 4
- 239000003550 marker Substances 0.000 description 4
- 229910052751 metal Inorganic materials 0.000 description 4
- 239000002184 metal Substances 0.000 description 4
- 238000007069 methylation reaction Methods 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 230000002441 reversible effect Effects 0.000 description 4
- BAZAXWOYCMUHIX-UHFFFAOYSA-M sodium perchlorate Chemical compound [Na+].[O-]Cl(=O)(=O)=O BAZAXWOYCMUHIX-UHFFFAOYSA-M 0.000 description 4
- 229910001488 sodium perchlorate Inorganic materials 0.000 description 4
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 4
- 230000005026 transcription initiation Effects 0.000 description 4
- 238000001890 transfection Methods 0.000 description 4
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 3
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- 101100245221 Mus musculus Prss8 gene Proteins 0.000 description 3
- 229940026233 Pfizer-BioNTech COVID-19 vaccine Drugs 0.000 description 3
- 229960000583 acetic acid Drugs 0.000 description 3
- DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 description 3
- 239000007795 chemical reaction product Substances 0.000 description 3
- 239000012141 concentrate Substances 0.000 description 3
- 238000004821 distillation Methods 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 238000004255 ion exchange chromatography Methods 0.000 description 3
- 108700021021 mRNA Vaccine Proteins 0.000 description 3
- 229940126582 mRNA vaccine Drugs 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 3
- 159000000000 sodium salts Chemical class 0.000 description 3
- 238000001308 synthesis method Methods 0.000 description 3
- 230000002194 synthesizing effect Effects 0.000 description 3
- BCNZYOJHNLTNEZ-UHFFFAOYSA-N tert-butyldimethylsilyl chloride Chemical compound CC(C)(C)[Si](C)(C)Cl BCNZYOJHNLTNEZ-UHFFFAOYSA-N 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 3
- 239000012096 transfection reagent Substances 0.000 description 3
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 3
- DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 description 3
- 229940045145 uridine Drugs 0.000 description 3
- UHDGCWIWMRVCDJ-UHFFFAOYSA-N 1-beta-D-Xylofuranosyl-NH-Cytosine Natural products O=C1N=C(N)C=CN1C1C(O)C(O)C(CO)O1 UHDGCWIWMRVCDJ-UHFFFAOYSA-N 0.000 description 2
- LIKMAJRDDDTEIG-UHFFFAOYSA-N 1-hexene Chemical compound CCCCC=C LIKMAJRDDDTEIG-UHFFFAOYSA-N 0.000 description 2
- PGZVFRAEAAXREB-UHFFFAOYSA-N 2,2-dimethylpropanoyl 2,2-dimethylpropanoate Chemical compound CC(C)(C)C(=O)OC(=O)C(C)(C)C PGZVFRAEAAXREB-UHFFFAOYSA-N 0.000 description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
- ROFVEXUMMXZLPA-UHFFFAOYSA-N Bipyridyl Chemical group N1=CC=CC=C1C1=CC=CC=N1 ROFVEXUMMXZLPA-UHFFFAOYSA-N 0.000 description 2
- 239000004215 Carbon black (E152) Substances 0.000 description 2
- 208000035473 Communicable disease Diseases 0.000 description 2
- UHDGCWIWMRVCDJ-PSQAKQOGSA-N Cytidine Natural products O=C1N=C(N)C=CN1[C@@H]1[C@@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-PSQAKQOGSA-N 0.000 description 2
- 102100027304 Eukaryotic translation initiation factor 4E Human genes 0.000 description 2
- 101710091918 Eukaryotic translation initiation factor 4E Proteins 0.000 description 2
- 101001082073 Homo sapiens Interferon-induced helicase C domain-containing protein 1 Proteins 0.000 description 2
- 102100027353 Interferon-induced helicase C domain-containing protein 1 Human genes 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- 239000012124 Opti-MEM Substances 0.000 description 2
- 101710124239 Poly(A) polymerase Proteins 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- UHDGCWIWMRVCDJ-ZAKLUEHWSA-N cytidine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-ZAKLUEHWSA-N 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- 238000006212 diphosphorylation reaction Methods 0.000 description 2
- 241001493065 dsRNA viruses Species 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 239000007850 fluorescent dye Substances 0.000 description 2
- 229930195733 hydrocarbon Natural products 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 239000007972 injectable composition Substances 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- 239000011630 iodine Substances 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 238000003670 luciferase enzyme activity assay Methods 0.000 description 2
- 229910001629 magnesium chloride Inorganic materials 0.000 description 2
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 2
- 235000019341 magnesium sulphate Nutrition 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 230000011987 methylation Effects 0.000 description 2
- 230000003472 neutralizing effect Effects 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 238000001543 one-way ANOVA Methods 0.000 description 2
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 125000000714 pyrimidinyl group Chemical group 0.000 description 2
- 239000011535 reaction buffer Substances 0.000 description 2
- 238000012827 research and development Methods 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 238000010839 reverse transcription Methods 0.000 description 2
- 238000004007 reversed phase HPLC Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 2
- 235000019345 sodium thiosulphate Nutrition 0.000 description 2
- ATHGHQPFGPMSJY-UHFFFAOYSA-N spermidine Chemical compound NCCCCNCCCN ATHGHQPFGPMSJY-UHFFFAOYSA-N 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 229940113082 thymine Drugs 0.000 description 2
- DQWPFSLDHJDLRL-UHFFFAOYSA-N triethyl phosphate Chemical compound CCOP(=O)(OCC)OCC DQWPFSLDHJDLRL-UHFFFAOYSA-N 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- ONBQEOIKXPHGMB-VBSBHUPXSA-N 1-[2-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-4,6-dihydroxyphenyl]-3-(4-hydroxyphenyl)propan-1-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 ONBQEOIKXPHGMB-VBSBHUPXSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- QNIZHKITBISILC-RPKMEZRRSA-N 2-amino-9-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)-2-methyloxolan-2-yl]-3h-purin-6-one Chemical compound C1=NC(C(NC(N)=N2)=O)=C2N1[C@]1(C)O[C@H](CO)[C@@H](O)[C@H]1O QNIZHKITBISILC-RPKMEZRRSA-N 0.000 description 1
- 125000001731 2-cyanoethyl group Chemical group [H]C([H])(*)C([H])([H])C#N 0.000 description 1
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
- BSKHPKMHTQYZBB-UHFFFAOYSA-N 2-methylpyridine Chemical compound CC1=CC=CC=N1 BSKHPKMHTQYZBB-UHFFFAOYSA-N 0.000 description 1
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 1
- LRSASMSXMSNRBT-UHFFFAOYSA-N 5-methylcytosine Chemical compound CC1=CNC(=O)N=C1N LRSASMSXMSNRBT-UHFFFAOYSA-N 0.000 description 1
- CKOMXBHMKXXTNW-UHFFFAOYSA-N 6-methyladenine Chemical compound CNC1=NC=NC2=C1N=CN2 CKOMXBHMKXXTNW-UHFFFAOYSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 101150014715 CAP2 gene Proteins 0.000 description 1
- 208000025721 COVID-19 Diseases 0.000 description 1
- 229920002271 DEAE-Sepharose Polymers 0.000 description 1
- 102000007260 Deoxyribonuclease I Human genes 0.000 description 1
- 108010008532 Deoxyribonuclease I Proteins 0.000 description 1
- 102000016911 Deoxyribonucleases Human genes 0.000 description 1
- 108010053770 Deoxyribonucleases Proteins 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102000009617 Inorganic Pyrophosphatase Human genes 0.000 description 1
- 108010009595 Inorganic Pyrophosphatase Proteins 0.000 description 1
- 229930010555 Inosine Natural products 0.000 description 1
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 101100438378 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) fac-1 gene Proteins 0.000 description 1
- 101100326803 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) fac-2 gene Proteins 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 108010010677 Phosphodiesterase I Proteins 0.000 description 1
- 102000055027 Protein Methyltransferases Human genes 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical group C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- 108091034057 RNA (poly(A)) Proteins 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 241000315672 SARS coronavirus Species 0.000 description 1
- 206010046865 Vaccinia virus infection Diseases 0.000 description 1
- FOGROKSBHHVCFH-IBNKKVAHSA-N [[(2r,3s,4r,5s)-5-(2,4-dioxo-1h-pyrimidin-5-yl)-3,4-dihydroxy-5-methyloxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate Chemical compound C=1NC(=O)NC(=O)C=1[C@]1(C)O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O FOGROKSBHHVCFH-IBNKKVAHSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 125000005907 alkyl ester group Chemical group 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 230000002457 bidirectional effect Effects 0.000 description 1
- 238000006065 biodegradation reaction Methods 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 238000002619 cancer immunotherapy Methods 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 229940126142 compound 16 Drugs 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 150000005690 diesters Chemical class 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 239000001177 diphosphate Substances 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 238000010362 genome editing Methods 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 150000002411 histidines Chemical class 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- AFQIYTIJXGTIEY-UHFFFAOYSA-N hydrogen carbonate;triethylazanium Chemical compound OC(O)=O.CCN(CC)CC AFQIYTIJXGTIEY-UHFFFAOYSA-N 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 229960003786 inosine Drugs 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 101710082804 mRNA cap methyltransferase Proteins 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000001035 methylating effect Effects 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- NCGWKCHAJOUDHQ-UHFFFAOYSA-N n,n-diethylethanamine;formic acid Chemical compound OC=O.OC=O.CCN(CC)CC NCGWKCHAJOUDHQ-UHFFFAOYSA-N 0.000 description 1
- PSHKMPUSSFXUIA-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 150000003833 nucleoside derivatives Chemical class 0.000 description 1
- 125000003835 nucleoside group Chemical group 0.000 description 1
- 229920002113 octoxynol Polymers 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 229920001467 poly(styrenesulfonates) Polymers 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- IGFXRKMLLMBKSA-UHFFFAOYSA-N purine Chemical compound N1=C[N]C2=NC=NC2=C1 IGFXRKMLLMBKSA-UHFFFAOYSA-N 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 238000009256 replacement therapy Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 229940063673 spermidine Drugs 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- HWCKGOZZJDHMNC-UHFFFAOYSA-M tetraethylammonium bromide Chemical compound [Br-].CC[N+](CC)(CC)CC HWCKGOZZJDHMNC-UHFFFAOYSA-M 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000014621 translational initiation Effects 0.000 description 1
- 239000001226 triphosphate Substances 0.000 description 1
- 125000002264 triphosphate group Chemical group [H]OP(=O)(O[H])OP(=O)(O[H])OP(=O)(O[H])O* 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 208000007089 vaccinia Diseases 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H1/00—Processes for the preparation of sugar derivatives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
Definitions
- the present invention relates to a cap analog and a protein expression method using the same, and more specifically, to a cap analog, a 5' capped mRNA containing the cap analog, and a pharmaceutical composition for expressing a desired peptide or protein containing the 5' capped mRNA. , and a method for producing a desired peptide or protein using the 5' capped mRNA.
- mRNA messenger RNA
- the synthesized mRNA is transported out of the nucleus and undergoes a translation process in which a specific protein is synthesized through ribosomes in the cytoplasm.
- the 5' capping structure (referred to as a 5' cap 0 mRNA structure) can protect the 5' end of mRNA from biodegradation by 5' exonuclease, and affects the movement of mRNA from the nucleus to the cytoplasm.
- the 5' capping structure is recognized by eukaryotic translation initiation factor 4E (eIF4E) and plays an important role in protein expression by forming a translation initiation complex.
- eIF4E eukaryotic translation initiation factor 4E
- the 2' hydroxyl group of the first nucleotide in which 7-methylguanosine is linked through a 5'-triphosphate chain must have a methylated structure (Cap1 mRNA).
- MDA5 intracellular sensor protein
- recognizing the Cap0 structure recognizes the 2' hydroxyl group when exogenous mRNA of the Cap0 structure is introduced into the body, resulting in an immune inflammatory response. , which impairs the binding of mRNA to elF4E, thereby inhibiting protein expression.
- exogenous Cap1 mRNA in which the 2' OH is methylated does not induce an immune response because it is not recognized by MDA5 even when introduced into the body, and thus it is suitable for clinical use because it can induce relatively high protein expression.
- an enzyme capable of methylating the 2' hydroxyl group of the nucleotide such as vaccinia mRNA (nucleoside-2'-O) methyltransferase, must be additionally treated.
- This traditional capping method has disadvantages in that the manufacturing cost is high due to the unit price of the enzyme, the number of treatments, and the like, and it is difficult to control the enzyme reaction.
- the co-transcriptional capping method refers to a method of synthesizing mRNA constituting the 5' end of the cap analog by simultaneously introducing a chemically synthesized cap analog during in vitro mRNA synthesis.
- the co-transcriptional capping method starts with the first generation dimeric cap analog mCAP ( 7m G (5 ' ) ppp (5 ' ) G) and then the third generation Trilink's trinucleotide cap analogue Cleancap® ( 7m G (3 ' OMe) pppN (2'OMe) pN) (U.S. Patent No.
- mCAP has a lower production cost compared to the traditional capping method, but is limited to the 5' cap 0 mRNA structure and competes with guanosine triphosphate (GTP) when mCAP forms base pairing with the DNA template. It does have the downside of working. In order to perform base pairing on the DNA template more favorably than GTP, it is necessary to add 4 to 10 times the amount of GTP used, which increases the production cost. In addition to this, mCAP in the form of dinucleotides sometimes undergoes reverse coupling, resulting in bidirectional transcription initiation, resulting in a decrease in the efficiency of forward mRNA synthesis in vitro.
- GTP guanosine triphosphate
- ARCA anti-reverse cap analog
- US Patent 7,074,596 ARCA has a 7m G (3'OMe) pppG or 7m G (2' OMe) pppG structure in which either the 2' or 3' hydroxyl group of 7-methylguanosine is substituted with a methoxy group in 7m GpppG, a dimer.
- ARCA As a dimeric cap analog, it completely blocks reverse transcription initiation by preventing reverse binding of the cap analog RNA 9:1108-1122 (2003).
- 7m G (3'OMe) pppA (2'OMe) pG it is a trinucleotide cap in which the 3' hydroxyl group of 7-methylguanosine is methylated. It showed better performance than 7m GpppA (2'OMe) pG, which is a roxyl cap.
- BNT162b2 A commercially available mRNA vaccine based on the above-described Cleancap structure ( 7m G (3'OMe) pppA (2'OMe) pG) is Pfizer/BioNTech's BNT162b2.
- BNT162b2 was developed to respond to an infectious disease caused by severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2), an RNA virus that caused a global pandemic.
- SARS-CoV-2 severe acute respiratory syndrome coronavirus type 2
- BNT162b2 which is manufactured with Cleancap as a key raw material, suffered from a raw material supply shortage at one time because it was difficult to meet the demand to respond to the worldwide Covid-19 pandemic. Rapid and economical production and supply of raw materials are required for mass production of mRNA vaccines that can respond appropriately to RNA virus infectious diseases with high transmissibility. Additional research and development must be done.
- G is guanosine
- 7m G is 7-methylguanosine
- N is any one of adenosine, cytidine, guanosine, or uridine
- Me means methyl
- Im means imidazolide.
- pN (2'OMe) pN which is a reactant used in the final manufacturing process
- the main factors that increase the production cost and synthesis period in the entire manufacturing process when mass-producing the cap analogues of Trilink are the purification steps using ion exchange chromatography (mainly DEAE resin) that must be performed between steps of the manufacturing process.
- ion exchange chromatography mainly DEAE resin
- a large amount of buffer solution mainly TEAB (triethylammonium bicarbonate) buffer
- TEAB triethylammonium bicarbonate
- Flash chromatography or Dowex 1 ⁇ 2 ion exchange chromatography should be performed at each step, and the yield of each step is low, making it difficult to mass-produce and increasing the production cost.
- Recently, research and development have been conducted to increase the synthesis efficiency of 3'-methoxy guanosine, but the process step is lengthened or it is still difficult to isolate a monoether substance substituted with 3' methoxy. This is a major factor in increasing the cost of raw materials for the synthesis of cap analogues.
- Patent Document 1 US 7,074,596
- Patent Document 2 US 10,913,768
- Non-Patent Document 1 RNA 9: 1108-1122 (2003)
- One aspect is to provide a cap analog that can increase the efficiency of in vitro synthesis of 5'-capped mRNA molecules, increase the protein expression efficiency of capped mRNA, and enable economical production of the cap analog itself.
- Another aspect is to provide an intermediate manufacturing method for preparing the cap analogue.
- Another aspect is to provide mRNA 5' capped with the cap analog.
- Another aspect is to provide a method for producing mRNA using the cap analog.
- Another aspect is to provide a composition or kit for preparing 5' capped mRNA, including the cap analog.
- Another aspect is to provide a pharmaceutical composition for expressing a desired peptide or protein, including the cap analog.
- Another aspect is to provide a cell containing an mRNA 5' capped with the cap analogue.
- Another aspect is to provide a cell containing a protein or peptide translated from mRNA 5' capped with the cap analogue.
- One aspect provides a compound of Formula 1 or a pharmaceutically acceptable salt thereof:
- n 0, 1, or 2;
- R 3 is a methoxy group
- Z and Z' are each independently a natural nitrogen base.
- Another aspect provides an aqueous composition
- aqueous composition comprising the compounds of Formulas 1a and 1b below in a molar ratio of 0.65 ⁇ 0.05:1:
- each M of M 3 does not exist independently of each other, or is a monovalent cation selected from the group consisting of Na + , Li + , NH 4 + and K + , or Mg 2+ , Zn 2+ , and Ca 2 A divalent cation selected from the group consisting of + , wherein M 3 is selected such that the compound is electrically neutral.
- Another aspect provides a cap analog comprising the compound of Formula 1.
- Another aspect provides an mRNA 5' capped with the cap analog.
- Another aspect provides a method for preparing mRNA, comprising including the cap analog during synthesis of mRNA.
- composition or kit for preparing 5' capped mRNA including the cap analog.
- Another aspect provides a pharmaceutical composition for expressing a desired peptide or protein, comprising an mRNA 5' capped with the cap analog and a pharmaceutically acceptable carrier.
- Another aspect provides a cell containing an mRNA 5' capped with the cap analog.
- Another aspect provides a cell containing a protein or peptide translated from mRNA 5' capped with the cap analog.
- R means C 1 ⁇ C 6 alkyl or C 1 ⁇ C 6 alkoxy
- Cap analogs according to one aspect do not need to selectively introduce a protecting group only at a specific position, such as Trilink's trinucleotide cap analog ( 7m G (3'OMe) pppA (2'OMe) pG), Since there is no need to purify the introduced compound, expensive starting materials such as 3'-methoxy guanosine are not required, and the manufacturing process can be simplified, the efficiency and economy of synthesis are high. While being improved, it has the advantage of enabling a superior level of expression efficiency of the capped mRNA when capping the mRNA.
- Trilink's trinucleotide cap analog 7m G (3'OMe) pppA (2'OMe) pG
- the cap analog has excellent advantages in terms of function and production cost, and thus, the mRNA containing the cap analog of the present disclosure can be very useful for treating or preventing diseases of mammals including humans.
- Example 1 is a graph showing 1 H NMR measurement results after preparing an intermediate compound (Example 8) according to one embodiment of the present invention.
- Example 2 is a graph showing 1 H NMR measurement results after preparing an intermediate compound (Example 9) according to one embodiment of the present invention.
- FIG. 3 is a graph showing 1 H NMR measurement results after preparing a compound (compound of Example 16) according to one embodiment of the present invention.
- IVT in vitro transcription
- Figure 5 shows the translation activity of mRNA produced by IVT reaction of each compound (compound of Example 15 or 16) or 7m G (3' OMe) pppA (2' OMe) pG according to one embodiment of the present invention.
- the result measured by transfecting the mRNA into the HeLa cell line is expressed as the amount of luciferase expression.
- Figure 6 shows the translational activity of mRNA produced by IVT reaction of each compound (compound of Example 15 or 16) or 7m G (3' OMe) pppA (2' OMe) pG according to one embodiment of the present invention.
- the result measured at 24 hours after transfecting the mRNA into the HeLa cell line is shown as the amount of luciferase expression.
- complementarity refers to the standard Watson/Crick base pairing rules.
- sequence “5'-A-G-T-C-3'” is complementary to the sequence "3'-T-C-A-G-5'".
- Complementarity need not be perfect; A duplicate may contain mismatched base pairs, degenerate, or unmatched nucleotides.
- the skilled person can empirically consider numerous variables including, for example, the length of the oligonucleotide, the base composition and sequence of the oligonucleotide, the incidence of mismatched base pairs, the ionic strength, the components of the hybridization buffer, and the reaction conditions to double double the number of variables. body stability can be determined.
- Complementarity can be "complete” or “total” if both nucleotide bases of the two nucleic acid strands are matched according to the recognized base pairing rules, and only some of the nucleotide bases of the cap analogue and the DNA target form a recognized base pair. It can be “partial” if it matches according to a rule, or it can be “absent” if neither of the nucleotide bases of the two nucleic acid strands match according to recognized base pairing rules.
- nitrogen base includes all naturally occurring nitrogen bases.
- the base rings most commonly found in naturally occurring nitrogenous bases are the purine and pyrimidine rings.
- Naturally occurring purine rings include, for example, adenine, guanine, and N6-methyladenine.
- Naturally occurring pyrimidine rings include, for example, cytosine, thymine, 5-methylcytosine, and uracil.
- Naturally occurring nucleosides are, for example, adenosine, guanosine, cytidine, thymidine, uridine, inosine, 7-methylguanosine or ribo, 2'-O-methyl or 2'- of uridine.
- Deoxyribo derivatives include, but are not limited to.
- C 1-n alkyl refers to a hydrocarbon radical chain of 1 to n carbons, linear or branched, saturated. Specific examples include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, t-butyl, n-pentyl, isopentyl, n-hexyl, and the like.
- C 1-n alkoxy refers to a hydrocarbon radical chain of 1 to n saturated carbons, linear or branched, bonded to oxygen. Specific examples include, but are not limited to, methoxy, ethoxy, propoxy, isobutoxy, n-butoxy, sec-butoxy, t-butoxy, pentoxy, hexoxy, and the like.
- in situ method means that the obtained product is subjected to the next step of the reaction in the original container as it is without an additional purification process.
- One aspect relates to a compound having the structure of Formula 1:
- n 0, 1, or 2;
- R 3 is a methoxy group
- Z and Z' are each independently a natural nitrogen base.
- the pharmaceutically acceptable salt refers to a salt commonly used in the pharmaceutical field, and may specifically be a base addition salt.
- the salt includes, for example, a monovalent metal salt, a divalent metal salt, an amine salt, or an amino acid salt.
- the monovalent metal salts include Na, Li, or K salts
- the divalent metal salts include Ca, Zn, or Mg salts
- the amine salts include trimethylamine, triethylamine, ammonia, pyridine, or picoline. salts, and the like
- the amino acid salts include, but are not limited to, arginine, lysine, or histidine salts.
- the pharmaceutically acceptable salt may be in the form of a salt that enables the compound of Formula 1 to form a stable, electrically neutral form in an aqueous liquid phase.
- the compound of Formula 1 or a pharmaceutically acceptable salt thereof may be, for example, a compound of Formula 1A below:
- n 0, 1, or 2;
- X 1 , X 2 , X 3 , and X 4 do not exist independently of each other, or are monovalent cations, divalent cations, or a combination thereof, wherein X 1 , X 2 , X 3 , and X 4 is A compound of Formula 1A is selected to be electrically neutral;
- R 3 is a methoxy group
- Z and Z' are each independently a natural nitrogen base.
- the monovalent cation is selected from the group consisting of Na + , Li + , NH 4 + and K +
- the divalent cation is selected from the group consisting of Mg 2+ , Zn 2+ and Ca 2+ do.
- R' is a compound that is C 2 -C 6 alkyl or C 2 -C 6 alkoxy.
- R' is methyl, ethyl, isopropyl, isopropoxy, t-butyl, or t-butoxy.
- Z and Z' in Formula 1 are each independently a natural purine or pyrimidine base moiety. More specifically, Z and Z' may each independently be selected from the group consisting of guanine, adenine, cytosine, thymine, and uracil. In one embodiment, Z and Z' are adenine and guanine, respectively.
- the structural isomers present at the 2' or 3' position of guanosine form a mixture in dynamic equilibrium with each other.
- the ratio of each regioisomer in dynamic equilibrium is It may vary depending on the structure, and may also vary depending on the surrounding environment (eg, temperature, pH).
- the compound of Formula 1 is a compound selected from the group consisting of the compounds listed in Table 1 below or a pharmaceutically acceptable salt thereof:
- G is guanosine
- 7m G is 7-methylguanosine
- A is adenosine
- Me is methyl.
- Another aspect provides an aqueous composition
- aqueous composition comprising the compounds of Formulas 1a and 1b below in a molar ratio of 0.65 ⁇ 0.05:1:
- each M of M 3 does not exist independently of each other, or is a monovalent cation selected from the group consisting of Na + , Li + , NH 4 + and K + , or Mg 2+ , Zn 2+ , and Ca 2 A divalent cation selected from the group consisting of + , wherein M 3 is selected such that the compound is electrically neutral.
- M 3 may indicate that all three Ms may be NH 4 + , one M of M 3 is Ca 2+ , one M is K + , and one M is absent.
- each M of M 3 is Na + .
- the pH of the aqueous composition is between 1.0 and 8.0.
- the compounds of Formulas 1a and 1b may be present as a mixture in a molar ratio of 0.65 ⁇ 0.05:1 in an aqueous composition at, for example, 25° C. ⁇ 5, pH 1.0 to 8.0.
- the compound of Formula 1 may be prepared, for example, according to the methods exemplified in the Examples below. A person skilled in the art may prepare the compound by modifying the reaction conditions, reaction sequence, and reaction compound by appropriately modifying the methods exemplified in the following examples.
- G is guanosine
- 7m G is 7-methylguanosine
- N is any one of guanine, adenine, cytosine, or uracil
- R' is C 1 -C 6 alkyl or C 1 -C 6 alkoxy
- Im is an imidazolide.
- R means C 1 ⁇ C 6 alkyl or C 1 ⁇ C 6 alkoxy
- the alkali condition may be specifically pH 9.5 to 11.5, and may be formed using, for example, sodium hydroxide.
- the pH 1.5 to 4.5 which is a weakly acidic condition, may be formed using, for example, acetic acid.
- R means C 1 ⁇ C 6 alkyl or C 1 ⁇ C 6 alkoxy
- imidazole, triphenylphosphine, 2,2-dipyridyl disulfide, and triethylamine may be reacted together as an activating reagent to help imidazole coupling.
- Reaction Scheme 3 can be briefly represented by the following abbreviation.
- G is guanosine
- 7m is 7-methylguanosine
- Me is methyl
- Im is imidazolide.
- the compound of Formula 1 can be prepared by a total of 4 steps, purification can be performed after each step, and then the next step can be performed. Thus, 4 purification steps are required. This means that the number of purifications is reduced by one time compared to the conventional preparation method of TriLink's commercially available cap analog requiring five intermediate purification processes. Therefore, the compound of Formula 1 can be produced more economically because the number of processes and purification times are reduced compared to the conventionally known methods for preparing cap analogues.
- the purification method may be performed independently for each step through ion chromatography, reverse phase chromatography, and the like.
- the purification method is reverse phase chromatography.
- the most expensive part of the pure raw material cost for the preparation of cap analogues is the starting material 3' -O-methylguanosine nucleoside (G (3' OMe) ) is the unit price of the raw material, which requires a difficult process of selectively inducing methylation of only the 3' hydroxyl among the three hydroxyl groups of guanosine nucleoside, and selective purification of only the 3' monoesterification product. Because it has to go through a purification process.
- the compound of Chemical Formula 1 may be prepared using inexpensive guanosine monophosphate as a starting material.
- the mRNA capped with the compound of Formula 1 in the form of a monoester has a higher protein expression efficiency than conventional Trilink's trinucleotide 3'-methoxy cap analogue ( 7m G (3'OMe) pppA (2'OMe) pG). Even if it is higher than the case, it is possible to ultimately reduce the cost required for protein synthesis.
- the compound of Formula 1 in the form of a diester in which both 2'-OH and 3'-OH, which are other embodiments of the compound of Formula 1, are esterified, and the desired product is a diesterate It has the advantage that it can be produced without monoesterification at a selective position and separation and purification of the monoesterified product.
- 3' -O-methylguanosine nucleoside a starting material for the production of conventional cap analogs
- guanosine monophosphate a starting material for the production of cap analogs of the present invention.
- the compound of Formula 1 can be produced with significantly higher economic efficiency than conventional cap analog compounds.
- the cap analog of the compound of Formula 1 can be economically prepared in terms of time and cost through a reduction in the number of synthetic steps and purification compared to the conventional cap analog of trinucleotide manufactured by Trilink.
- the purification process may be performed with a reversed-phase column, and since a reversed-phase column is more efficient than a conventional ion exchange column, the reversed-phase column purification process may further contribute to the economics of the method for preparing the compound of Formula 1.
- the total number of purifications can be reduced by one in the entire process.
- the conventional cap analog synthesis method requires the product in each step to undergo ion exchange column purification, whereas the synthesis method for the compound of Formula 1 of the present application produces 1 per column volume compared to the same volume of ion exchange column. Purification is possible only with a reversed-phase column with about 10 times higher injection amount of the object to be purified. Therefore, the preparation method of the compound of Formula 1 can reduce the cost of raw materials for purification of triethylamine, resin, etc. used for the buffer by about 60 to 80%.
- the compound of Formula 1 can be used as a cap analogue for 5' capping of mRNA during in vitro mRNA synthesis. That is, during the in vitro mRNA synthesis, the compound of Formula 1 as a cap analog may be simultaneously introduced to synthesize an mRNA composed of a cap analog at the 5' end.
- Another aspect provides a cap analog comprising the compound of Formula 1.
- the cap analog may be the compound of Formula 1 itself, or may further include a hybridization sequence that may be complementary to a sequence on a DNA template at an initiation site in addition to the compound of Formula 1.
- the length of the hybridization sequence of cap analogs for use in the methods and compositions provided herein depends on several factors, including the identity of the template nucleotide sequence and the temperature at which such primers hybridize to the DNA template or are used during in vitro transcription.
- the desired length of a hybridized nucleotide sequence of a cap analog for use in transcription can be readily determined by routine experimentation by one skilled in the art.
- the length of hybridization nucleotides can be determined based on the desired hybridization specificity or selectivity.
- the cap analog is about 3 to about 9 nucleotides in length (including cap), more specifically about 3 to about 7 nucleotides, and even more specifically about 3 to about 5 nucleotides in length. In one embodiment the cap analog is 3 nucleotides in length.
- the length of the hybridization sequence within the cap analog may be equal to or shorter than the overall length of the cap analog.
- 5' capped mRNA can be prepared.
- one specific aspect provides a method for producing 5' capped mRNA, comprising including during the synthesis of mRNA a cap analog comprising the compound of Formula 1.
- composition or kit for preparing 5' capped mRNA including a cap analogue containing the compound of Formula 1.
- cap analogue comprising the compound of formula 1 for the synthesis of mRNA.
- an mRNA 5' capped with a cap analog comprising the compound of Formula 1 is provided.
- a method for preparing 5' capped mRNA using a cap analogue including the compound of Formula 1 may be performed according to any method known in the art.
- the 5' capped mRNA can be prepared by a co-transcriptional capping method, which is an mRNA synthesis method in which a cap analog constitutes the 5' end by simultaneously introducing a chemically synthesized cap analog during in vitro mRNA synthesis.
- a co-transcriptional capping method which is an mRNA synthesis method in which a cap analog constitutes the 5' end by simultaneously introducing a chemically synthesized cap analog during in vitro mRNA synthesis.
- the step of introducing the cap analog, which is a compound of Formula 1 into a mixture containing RNA polymerase under conditions in which transcription is effected by RNA polymerase of a polynucleotide template; and incubating the mixture for a time sufficient to permit transfer of the template.
- the cap analog comprising the compound of formula 1 according to the above aspect increases the efficiency of transcription of mRNA in vitro compared to the efficacy of initiation using standard GTP, ATP, CTP or UTP, and then capping the transcribed capping in the translation process It can increase the efficiency of protein expression of mRNA. Due to the enhancement of the transcription efficiency, the synthesis of mRNA is, for example, about 10%, about 20%, about 40%, about 60%, about 80%, about 90%, about It may be increased by 100%, about 150%, about 200% or about 500%.
- the cap analog containing the compound of Formula 1 according to the above aspect is a conventional Trilink trinucleotide 3'-methoxy cap analog ( 7m G (3'OMe) pppA (2 'OMe) can be increased to higher levels than pG). More specifically, a cap analog in which only one of the 2' or 3' OH residues of the compound of Formula 1 is monoesterified is a conventional trinucleotide 3'-methoxy cap analog from Trilink ( 7m G (3'OMe ) pppA (2'OMe) pG) can increase the protein expression level of the 5' capped mRNA molecule to a significantly higher level (see Experimental Example 2).
- the cap analog containing the compound of Formula 1 has a protein expression efficiency equal to or higher than that of the 3rd generation cap analog, and the number of manufacturing and purification processes of the cap analog itself can be reduced and the purification efficiency can be increased. It has the advantage of lowering the manufacturing cost.
- the method for producing 5' capped mRNA may further add at least one modified NTP to the transcription reaction. Modification of the at least one modified NTP does not substantially impair RNA polymerase mediated synthesis of mRNA.
- the modified NTP may include, for example, one or more modified nucleoside bases, one or more modified sugars, or one or more modified 5'-triphosphates. This modified NTP can be incorporated onto the 3'-end of the cap analog, which supports further extension of the primer without blocking transcription.
- the modifying group of the modified NTP may be a detectable label or a detectable marker. Thus, after transcription, prepared mRNA containing a detectable label or marker can be identified by size, mass, color and/or affinity capture.
- the detectable label or marker is a fluorescent dye;
- the affinity capture label is biotin.
- one or more components of the transcriptional response can be labeled with a detectable label or marker.
- a detectable label or marker can be identified by, for example, size, mass, affinity capture or color.
- the detectable label is a fluorescent dye;
- the affinity capture label is biotin.
- the kit or composition for preparing the 5' capped mRNA may contain any transcription reagent (eg, FLuc mRNA) for the synthesis of normal mRNA. More specifically, the kit comprises a cap analogue; containers marked for transcription; instructions for performing mRNA synthesis; one or more reagents selected from the group consisting of one or more unmodified NTPs, one or more modified NTPs (e.g., methylpseudouridine 5'-triphosphate), RNA polymerase, other enzymes, reaction buffers, magnesium, and DNA templates may contain.
- any transcription reagent eg, FLuc mRNA
- the kit comprises a cap analogue; containers marked for transcription; instructions for performing mRNA synthesis; one or more reagents selected from the group consisting of one or more unmodified NTPs, one or more modified NTPs (e.g., methylpseudouridine 5'-triphosphate), RNA polymerase, other enzymes, reaction buffers, magnesium
- a 5' capped mRNA prepared using a cap analog includes the cap analog in its structure, and can be used to express a protein in vivo by administering the 5' capped mRNA to a living body.
- another aspect provides a method for expressing a desired peptide or protein in vivo by administering an mRNA 5' capped with the cap analog in vivo.
- compositions for expressing a desired peptide or protein comprising an mRNA 5' capped with the cap analog and a pharmaceutically acceptable carrier.
- a desired effect of treating or preventing a disease can be obtained in vivo. Therefore, it can be used for the treatment or prevention of any disease that can be treated or prevented according to the expression of the peptide or protein.
- Diseases that can be treated or prevented by the expression of a specific peptide or protein are known, and the pharmaceutical composition can be used to prevent or treat a desired disease by inducing the expression of the peptide or protein.
- another aspect provides a pharmaceutical use for using the mRNA 5' capped with the cap analog for the prevention or treatment of any disease that is effective by in vivo expression of a peptide or protein.
- the pharmaceutical composition and treatment or prevention method may be used for gene replacement therapy, genome editing, cancer immunotherapy, or treatment or prevention using a vaccine.
- the pharmaceutical composition is an mRNA vaccine.
- the pharmaceutical composition may be formulated for administration by injection, or by any other suitable route known to those skilled in the art for treating or preventing a particular condition.
- Injectable compositions include, for example, sterile physiological saline as a pharmaceutically acceptable carrier.
- Injectable compositions may also be formulated as suspensions in lipids or phospholipids, liposomal suspensions, or aqueous emulsions. Methods of formulating the pharmaceutical composition are well known to those skilled in the art.
- the pharmaceutical composition may contain mRNA containing the cap analog as an active ingredient at a concentration of about 0.01% to 1%.
- concentration may vary depending on the frequency of administration, dosage, administration method, and the like.
- the pharmaceutical composition may be administered to a mammal, specifically a human, and the dosage may vary depending on the subject's health condition, severity of disease, weight, age, race, etc. An expert can determine the appropriate dosage.
- the dosage for humans is in the range of 0.0001 to 100 mg/day, more specifically in the range of about 0.1 to 50 mg/day.
- the mRNA capped 5' with the cap analog according to the above aspect can be introduced into cells in vivo or in vitro to express proteins or peptides.
- Another aspect provides a cell containing an mRNA 5' capped with a cap analog according to the first aspect.
- Another aspect provides a cell containing a protein or peptide translated from an mRNA 5' capped with a cap analog according to the first aspect.
- TEP triethyl phosphate
- the reaction solution was separated using a C18 column (50 x 250 mm) and azeotroped with 50 mL of methanol 4 times to obtain 3.79 g of the triethylammonium salt of the target compound (yield: 60.0%) (4).
- reaction solution was added to a solution of 2.45 g (20 mmol) of sodium perchlorate dissolved in 430 mL of acetone, cooled to 4 ° C, and the resulting crystals were filtered, washed with cold acetone, and vacuum dried.
- Dried im-pG (2',3' Pivaloyl) was added to 30 mL of dimethylformamide, 1.36 g (10 mmol) of zinc chloride, and 5.98 g (30 mmol) of triethylammonium phosphate were added, followed by 3 to 16 hours at room temperature. Stir.
- reaction solution was extracted three times with 150 mL of dichloromethane to remove unreacted dimethyl sulfate, and then the aqueous layer was adjusted to pH 5.5 and 500 mL of distilled water was added thereto.
- the reaction solution was separated from pp7mG (2', 3' Pivaloyl) using a C18 column (50 x 250 mm), distilled and vacuum dried to obtain 1.74 g of triethylammonium salt (yield: 80%) (6).
- the reaction solution was added to a solution of 847 mg (6.92 mmol) of sodium perchlorate dissolved in 175 mL of acetone, cooled to 4 ° C, and the resulting crystals were filtered, washed with cold acetone, and vacuum dried to obtain 967 mg of the target compound (yield: 80.0%). ) was obtained (7).
- Example 8 Preparation of 7-methyl-2' or 3'-monopivaloyl-guanosine monophosphate (p7mG (2' or 3' monopivaloyl)) (8)
- guanosine monophosphate was used as starting material without further treatment. 5 g (11.8 mmol) of guanosine monophosphate was dissolved in 50 ml of distilled water and titrated to pH 9.5 using 1M sodium hydroxide. 8.79 g (47.2 mmol) of pivalic anhydride was added at room temperature and stirred at room temperature. It was reacted for 4 to 12 hours while maintaining pH 9.5 to 9.6 using 1M sodium hydroxide at room temperature. After completion of the reaction, 50% acetic acid was added to adjust the pH to 4.5, and 14.9 g (118 mmol) of dimethyl sulfate was slowly added over 30 minutes, followed by stirring for 4 hours.
- reaction solution was maintained at 4.0 ⁇ 0.5 using 1M sodium hydroxide.
- the reaction solution was extracted three times with 150 mL of dichloromethane to remove unreacted dimethyl sulfate, and the aqueous layer was titrated to pH 5.5.
- 5'-O-DMT-N6-benzoyl-2' -methoxy-adenosine amidite it was obtained commercially and used as a starting material without additional treatment. 1.43 g (3.28 mmol) of N2-isobutyryl-2',3'-diacetoxy-guanosine (11) and 3.78 g of 5'-O-DMT-N6-benzoyl-2'-methoxy-adenosine amidite (4.26 mmol) was dissolved in 28.4 mL of 1H-tetrazole (0.45 M acetonitrile solution, 12.79 mmol) and stirred at room temperature for 1 hour.
- 0.55 g of magnesium chloride was added to 27.5 mL of dimethylformamide and dissolved. 0.69 g (0.99 mmol) of Im-pp 7m G (2', 3' Pivaloyl) (7) and 0.5 g (0.55 mmol) of pA (2' OMe) pG (14) were added to the reaction solution and stirred at room temperature for 24 hours. did After the reaction was completed, 275 mL of 25 mM ethylenediaminetetraacetic acid aqueous solution was added dropwise to terminate the reaction, cooled to room temperature, and then neutralized with 1M sodium bicarbonate aqueous solution. The reaction solution was purified using a C18 column (50 x 250 mm) and vacuum dried after distillation.
- the transcription reaction mixture was prepared by adding polymerase, 2 KU/ml RNase inhibitory protein, 20 U/ml inorganic pyrophosphatase, 40 mM Tris HCl (pH 8.0), 50 mM magnesium chloride, and 10 mM dithiothreitol.
- transcription reaction using 7m G (3'OMe) pppA (2'OMe) pG (Cleancap AG (3' OMe) (trilink catalog N-7413) instead of the compound of Example 15 or 16)
- the transcription reaction mixture was reacted for 2 to 3 hours at 37° C.
- 2KU/mL DNase I was added to the reaction mixture to terminate the reaction, and the reaction was performed at 37° C. for 15 to 30 minutes.
- the mRNA after the reaction was purified using RNeasy maxi kit (Qiagen catalog # 75162) or by reverse-phase high-performance liquid chromatography according to the manufacturer's instructions.
- the total amount of mRNA synthesized using different cap analogues was divided by the input L-DNA content to calculate the total amount of mRNA.
- the IVT yield value according to was quantified. Specifically, the IVT yield value of 100 means that 1 ⁇ g L-DNA synthesized 100 ⁇ g mRNA. This can be calculated by the following [Equation 1].
- the IVT yield value [Equation 1] by the example compound is divided by the yield value of 7m G (3' OMe) pppA (2' OMe) pG [Equation 1] and then multiplied by 100 to obtain 7m G (3' OMe) pppA
- the IVT yield by the compound of Example 15 or 16 compared to (2' OMe) pG was expressed as a percentage (%) [see Equation 2].
- IVT yield value total amount of synthesized mRNA / amount of L-DNA input
- IVT yield (%) (IVT yield value by each example compound [Equation 1] / 7m G (3' OMe) pppA (2' OMe) IVT yield value by pG [Equation 1]) x 100
- IVT yield values by each Example and 7m G (3' OMe) pppA (2' OMe) pG were independently repeated three times, and significance was verified through One-way ANOVA and Tukey's hoc tests. The result is shown in FIG. 4 . It was confirmed that the compounds of Examples 15 and 16 of the present invention were synthesized in almost the same yield as the IVT yield of 7m G (3' OMe) pppA (2' OMe) pG, a conventional 3rd generation cap analogue.
- the translation activity of the mRNA produced by the IVT reaction of each of Example 15, Example 16, and 7m G (3' OMe) pppA (2' OMe) pG was evaluated by transfecting the corresponding mRNA into a HeLa cell line. did Before transfection, all mRNAs synthesized by the IVT reaction were subjected to a poly(A) tailing process.
- HeLa cells were cultured in DMEM supplemented with 10% FBS, 1% penicillin/streptomycin at 37° C. in an atmosphere of 5% CO 2 . After plating 1 ⁇ 10 4 HeLa cells per well, the next day the cells were transfected with 100 ng of mRNA per well using the transfection reagent ( messengergerMAX lipofectamine; Invitrogen catalog # LMRNA003): recommended by the transfection reagent manufacturer.
- the transfection reagent messengerMAX lipofectamine; Invitrogen catalog # LMRNA003
- transfection reagent 0.3 ⁇ L of transfection reagent was diluted in 5 ⁇ L of complex medium (Opti-MEM; Life technologies) in tube A and incubated for 10 minutes at room temperature, and in tube B, 200 ng of mRNA prepared in 10 ⁇ L of Opti-MEM was prepared by dilution. The solutions in tube A and tube B were mixed and incubated for 5 minutes at room temperature. Then, cells were transfected using the incubated mixed solution.
- complex medium Opti-MEM; Life technologies
- Renilla-Glo TM Luciferase Assay kit Promega catalog #E2710
- medium of transfected cells was After removal, 50 ⁇ l of phosphate buffer (PBS) was added. Thereafter, 50 ⁇ l of Renilla-GloTM Luciferase Assay reagent was added, mixed, and incubated for 10 minutes, and then luciferase activity was detected using a Varioskan LUX Multimode Microplate Reader (Thermo Fisher) (FIG. 5). All luciferase activity measurement tests were independently performed three times, and significance was verified through One-way ANOVA and Tukey's hoc tests.
- the mRNA capped with the compound (16) of Example 16 of the present invention has a higher luciferase level than mRNA capped with conventional 7m G (3' OMe) pppA (2' OMe) pG from 6 to 24 hours after transfection. activity was shown (FIG. 5). In addition, from the result at 24 hours after transfection, it can be inferred that the residual rate of the protein expressed by mRNA capped with compound 16 is higher (FIG. 6).
Abstract
Description
Claims (15)
- 청구항 1에 있어서, 상기 화합물은 하기 화학식 1A의 구조를 갖는 화합물:[화학식 1A]여기서,n = 0, 1, 또는 2이고;X1, X2, X3, 및 X4은 각각 독립적으로 존재하지 않거나, 1가 양이온, 2가 양이온, 또는 이들의 조합으로서, 이 때 X1, X2, X3, 및 X4 는 화학식 1A의 화합물이 전기적 중성이 되도록 선택되고;R1 및 R2는 각각 독립적으로 H 또는 C(=O)-R' 이고, 단, R1 및 R2 중 적어도 하나는 C(=O)-R' 이며, 여기에서 R' 은 C1~C6알킬 또는 C1~C6알콕시이고;R3은 메톡시기이고;Z 및 Z' 는 각각 독립적으로 천연 질소 염기이다.
- 청구항 2에 있어서, R' 은 C2~C6알킬 또는 C2~C6알콕시인 것인 화합물.
- 청구항 2에 있어서, 상기 1가 양이온은 Na, Li, NH4 + 및 K로 구성된 군에서 선택되고, 상기 2가 양이온은 Mg2+, Zn2+ 및 Ca2+로 구성된 군에서 선택되는 것인 화합물.
- 청구항 2에 있어서, Z, Z' 는 각각 독립적으로 구아닌, 아데닌, 시토신, 및 우라실로 이루어진 군으로부터 선택되는 것인 화합물.
- 청구항 7에 있어서, 상기 M3 중 각각의 M은 모두 Na+ 인 것인 수성 조성물.
- 청구항 7에 있어서, 상기 수성 조성물의 pH는 1.0 내지 8.0 인 것인 수성 조성물.
- 청구항 1 내지 9 중 어느 한 항에 정의된 화합물을 포함하는, 캡 유사체.
- 청구항 10에 따른 캡 유사체로 5' 캡핑된 mRNA.
- 청구항 10에 따른 캡 유사체를 포함하는, 5' 캡핑된 mRNA 제조용 조성물 또는 키트.
- 청구항 10에 따른 캡 유사체로 5' 캡핑된 mRNA 및 약학적으로 허용되는 담체를 포함하는, 목적하는 펩티드 또는 단백질 발현을 위한 약학 조성물.
- 하기 화학식 2의 화합물 또는 그 염을 수상의 알칼리 조건에서 하기 화학식 3의 화합물과 반응시켜 하기 화학식 4의 화합물 또는 그의 염을 제조하는 단계; 및화학식 4의 화합물 또는 그의 염을 인 시츄 방식으로 pH 1.5 ~ 4.5 조건에서 화학식 5의 화합물과 반응시키는 단계를 포함하는,하기 화학식 6의 화합물 또는 그의 염의 제조방법:[화학식 2][화학식 3][화학식 4][화학식 5][화학식 6]상기 화학식에서, R은 C1~C6알킬 또는 C1~C6알콕시를 의미하며, R1 및 R2는 각각 독립적으로 H 또는 C(=O)-R' 이며, 단, R1 및 R2 중 어느 하나는 H이며 나머지는 C(=O)-R이다.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA3230030A CA3230030A1 (en) | 2021-08-31 | 2022-08-31 | Mrna cap analogue and use thereof |
AU2022338639A AU2022338639A1 (en) | 2021-08-31 | 2022-08-31 | Mrna cap analogue and use thereof |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20210115942 | 2021-08-31 | ||
KR10-2021-0115942 | 2021-08-31 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2023033551A1 true WO2023033551A1 (ko) | 2023-03-09 |
Family
ID=85411417
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2022/013062 WO2023033551A1 (ko) | 2021-08-31 | 2022-08-31 | mRNA 캡 유사체와 및 이의 용도 |
Country Status (4)
Country | Link |
---|---|
KR (1) | KR20230032999A (ko) |
AU (1) | AU2022338639A1 (ko) |
CA (1) | CA3230030A1 (ko) |
WO (1) | WO2023033551A1 (ko) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2024051696A1 (zh) * | 2022-09-05 | 2024-03-14 | 广州市恒诺康医药科技有限公司 | 用于rna加帽的化合物及其应用 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030194759A1 (en) * | 2002-03-25 | 2003-10-16 | Edward Darzynkiewiz | Synthesis and use of anti-reverse mRBA cap analogues |
US20090324708A1 (en) * | 2006-11-06 | 2009-12-31 | Universidad Nacional De Quilmes | Compound having inhibitory activity on a rho-gtpase cell protein, a process for obtaining the same, pharmaceutical compositions comprising thereof and a method for the treatment of rho-gtpase cell protein-mediated condition |
KR20180050409A (ko) * | 2015-09-21 | 2018-05-14 | 트리링크 바이오테크놀로지즈, 인크. | 5'-캡핑된 rna를 합성하기 위한 조성물 및 방법 |
-
2022
- 2022-08-31 KR KR1020220110267A patent/KR20230032999A/ko unknown
- 2022-08-31 AU AU2022338639A patent/AU2022338639A1/en active Pending
- 2022-08-31 WO PCT/KR2022/013062 patent/WO2023033551A1/ko active Application Filing
- 2022-08-31 CA CA3230030A patent/CA3230030A1/en active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030194759A1 (en) * | 2002-03-25 | 2003-10-16 | Edward Darzynkiewiz | Synthesis and use of anti-reverse mRBA cap analogues |
US7074596B2 (en) | 2002-03-25 | 2006-07-11 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Synthesis and use of anti-reverse mRNA cap analogues |
US20090324708A1 (en) * | 2006-11-06 | 2009-12-31 | Universidad Nacional De Quilmes | Compound having inhibitory activity on a rho-gtpase cell protein, a process for obtaining the same, pharmaceutical compositions comprising thereof and a method for the treatment of rho-gtpase cell protein-mediated condition |
KR20180050409A (ko) * | 2015-09-21 | 2018-05-14 | 트리링크 바이오테크놀로지즈, 인크. | 5'-캡핑된 rna를 합성하기 위한 조성물 및 방법 |
US10913768B2 (en) | 2015-09-21 | 2021-02-09 | Trilink Biotechnologies, Inc. | Compositions and methods for synthesizing 5′-capped RNAs |
Non-Patent Citations (2)
Title |
---|
KORE ANILKUMAR, BUGARIN ALEJANDRO, SHANMUGASUNDARAM MUTHIAN: "Design and facile synthesis of new dinucleotide cap analog containing both 2` and 3'-OH modification on m7guanosine moiety", NUCLEOSIDES, NUCLEOTIDES & NUCLEIC ACIDS, TAYLOR & FRANCIS, US, vol. 34, no. 9, 1 September 2015 (2015-09-01), US , pages 611 - 619, XP009543953, ISSN: 1525-7770, DOI: 10.1080/15257770.2015.1041643 * |
TRAPERO ANA; PACITTO ANGELA; CHAN DANIEL SHIU-HIN; ABELL CHRIS; BLUNDELL TOM L.; ASCHER DAVID B.; COYNE ANTHONY G.: "Covalent inactivation of Mycobacterium thermoresistibile inosine-5′-monophosphate dehydrogenase (IMPDH)", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 30, no. 2, 9 November 2019 (2019-11-09), Amsterdam NL , XP086033939, ISSN: 0960-894X, DOI: 10.1016/j.bmcl.2019.126792 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2024051696A1 (zh) * | 2022-09-05 | 2024-03-14 | 广州市恒诺康医药科技有限公司 | 用于rna加帽的化合物及其应用 |
Also Published As
Publication number | Publication date |
---|---|
CA3230030A1 (en) | 2023-03-09 |
KR20230032999A (ko) | 2023-03-07 |
AU2022338639A1 (en) | 2024-02-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2022086140A1 (ko) | 5'-캡핑된 rna 합성용 올리고뉴클레오티드 | |
Mansuri et al. | Preparation of 1-(2, 3-dideoxy-. beta.-D-glycero-pent-2-enofuranosyl) thymine (d4T) and 2', 3'-dideoxyadenosine (ddA): general methods for the synthesis of 2', 3'-olefinic and 2', 3'-dideoxy nucleoside analogs active against HIV | |
EP0329348B1 (en) | 2',3'-Dideoxy-2',2'-difluoronucleosides | |
WO2021040356A1 (en) | C-nucleosides, c-nucleotides and their analogs, equivalents and prodrugs thereof for ectonucleotidase inhibition | |
WO2018182341A1 (ko) | 피롤로벤조디아제핀 이량체 전구체 및 이의 리간드-링커 접합체 화합물 | |
WO2014107024A1 (ko) | 항체-링커-약물 결합체, 그의 제조방법 및 그를 포함하는 항암제 조성물 | |
WO2023033551A1 (ko) | mRNA 캡 유사체와 및 이의 용도 | |
EP1163250A2 (en) | Improved synthesis of [2.2.1]bicyclo nucleosides | |
IL99451A (en) | Method for linking nucleosides by the siloxane bridge in the presence of a spatially inhibited base catalyst | |
WO2010072831A1 (en) | Sulfurizing reagents and their use for oligonucleotides synthesis | |
WO2018080127A1 (ko) | 아데노신 유도체를 포함하는 비알콜성 지방간염, 간섬유증 및 간경변증 예방 및 치료용 약학적 조성물 | |
WO2021137646A1 (ko) | 피롤로벤조디아제핀 유도체 및 이의 리간드-링커 접합체 | |
KR100329525B1 (ko) | 2',3'-디데히드로-3'-데옥시티미딘(d4t)의대단위제조를위한5-메틸우리딘공정 | |
WO2020149553A1 (ko) | 아릴 또는 헤테로아릴 유도체, 및 이를 유효성분으로 포함하는 키나아제 관련 질환 치료용 약학적 조성물 | |
Wagner et al. | A simple procedure for the preparation of protected 2′-O-methyl or 2′-O-ethyl ribonucleoside-3′-O-phosphoramidites | |
WO2022035303A1 (en) | Novel dioxoloisoquinolinone derivatives and use thereof | |
WO2020141923A9 (ko) | 안전성이 향상된 피롤로벤조디아제핀 이량체 화합물 및 이의 용도 | |
WO2023191342A1 (ko) | mRNA 캡 유사체 및 이의 용도 | |
WO2019031804A9 (ko) | 목적 유전자 발현 조절을 위한 대장균 및 코리네박테리움 글루타미쿰 셔틀 벡터 | |
WO2017164616A1 (en) | Methods for preparing 3'-amino-2',3'-dideoxyguanosine by using nucleoside phosphorylases derived from bacillus and adenosine deaminase derived from lactococcus | |
WO2021201352A1 (ko) | 신규한 벤지미다졸 유도체, 이의 제조방법 및 이의 항암제 용도 | |
Pochet et al. | Enzymatic synthesis of 1-(2-deoxy-β-D-ribofuranosyl) imidazole-4-carboxamide, a simplified DNA building block | |
WO2018079951A2 (ko) | 새로운 레졸신아렌 기반의 양친매성 화합물 및 이의 활용 | |
WO2013015661A2 (en) | Novel prodrugs of 5-(2,4-dihydroxy-5-isopropylphenyl)-n-ethyl-4-(5-methyl1-1,2,4-oxadiazol-3-yl)isoxazole-3-carboxamide | |
WO2021246846A1 (ko) | 신규한 몰포리노 올리고뉴클레오티드 유도체 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22865053 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2022338639 Country of ref document: AU Ref document number: AU2022338639 Country of ref document: AU |
|
ENP | Entry into the national phase |
Ref document number: 2022338639 Country of ref document: AU Date of ref document: 20220831 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 3230030 Country of ref document: CA |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112024003914 Country of ref document: BR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2024102878 Country of ref document: RU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2022865053 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2022865053 Country of ref document: EP Effective date: 20240402 |